Lofexidine - Britannia Pharmaceuticals

Drug Profile

Lofexidine - Britannia Pharmaceuticals

Alternative Names: BA-168; BritLofex; Lofexidine hydrochloride; LUCEMYRA; MDL-14042; MDL-14042A; RMI-14042A

Latest Information Update: 21 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Britannia Pharmaceuticals
  • Developer Britannia Pharmaceuticals; National Institute on Drug Abuse; US WorldMeds
  • Class Antihypertensives; Chlorobenzenes; Imidazolines; Phenyl ethers; Small molecules
  • Mechanism of Action Alpha 2 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Opioid abuse

Highest Development Phases

  • Marketed Opioid abuse

Most Recent Events

  • 16 May 2018 Registered for Opioid abuse in USA (PO)
  • 27 Mar 2018 Psychopharmacologic Drugs Advisory Committee recommends approval of lofexidine for Opioid abuse in USA
  • 21 Nov 2017 Preregistration for Opioid abuse in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top